Rhythm Buys Its Own Royalty and Swaps Its Own Endpoint — and the Stock Sits 26% Off the High

Q3 revenue jumped 29% sequentially on a $92.1M print; the equity is de-rating anyway. The real news is a $350M royalty buy-down, a floating-rate $750M facility, and a quietly changed Prader-Willi endpoint.

RYTM · Earnings Call · 2026-11-03

The quarter that should have been a breakout

Rhythm's third quarter was, on the tape of the business, its best quarter ever. Global net product sales of $92.1 million rose 29% sequentially from $71.3 million, with $67.5 million of that — 73% — coming from the U.S., and “More than 90% of that growth was attributable to the strong demand from patients with acquired HO.” — Hunter Smith, CFO or Finance Executive · 2026-11-03 That is the second full quarter of the hypothalamic obesity launch, and the underlying patient demand did not crack: more than 700 start forms since the March 19 launch, including 71 clinical-trial conversions, from more than 500 prescribers — roughly 200 of them first-time acquired HO writers in the quarter alone. The broadening base of prescribers is the number that matters, because repeat prescribers ticked up to 25% from 20%. The stock, meanwhile, closed the day 26.5% below its August peak of $117.60, having fallen 21.4% over the last 90 trading days. That is the tension at the center of this report: the P&L is inflecting, and the equity is de-rating. Revenue is not the problem — the reported base nearly tripled across the last two years and then grew another 29% in a single quarter The answer is partly mechanical. Rhythm's valuation still sits at 31.8x trailing revenue. Growth biotech trading at that multiple needs a clean story, and this quarter's story is anything but clean: a nine-figure cash commitment, a new secured lender, and a clinical pivot. Each one is rational on its own; together they read to investors as complexity.

The royalty buy-down is the real story

The headline number is the LG Chem amendment. Rhythm is paying $350 million in four installments — $70 million within 15 days of closing, then $100 million in September 2027, $100 million in September 2028, and $80 million in September 2029 — to cut its cross-portfolio royalty burden from a projected 5%–7% to a flat 1%.

We project that our cross-portfolio royalty obligations could have been 5%-7% under the previous agreement, pending future indication approvals for bivamelagon. We are buying down this royalty obligation to 1% flat, assuming U.S. approval for bivamelagon.
Hunter Smith, CFO or Finance Executive · 2026-11-03

Read the Q&A and the strategic logic is clearer than the press release. Asked whether this was a competitive process, CFO Hunter Smith said simply that the transaction was initiated by Rhythm. Management ran the math against risk-adjusted sell-side consensus and concluded “We think we're shaving about 5%” — Hunter Smith, CFO or Finance Executive · 2026-11-03 off the revenue line, with the upside accruing to Rhythm if the top line beats. And David Meeker was explicit that the original contract contained a structural poison pill: developing bivamelagon in new indications triggered an incremental royalty, which meant the company had an active economic disincentive to follow the science into Prader-Willi. That is now gone. The funding is where it gets less comfortable. Rhythm is drawing $250 million of a $750 million term loan facility with HealthCare Royalty and Blackstone at SOFR plus 4.6%, five years, no amortization, no equity kicker, no exit fee. Context matters here: Fed rate hike chatter is among the highest-momentum themes in the global keyword set this quarter, and Rhythm just swapped an equity-like royalty for floating-rate paper at exactly the wrong point in the cycle. Cash stood at $321 million at quarter-end, before the loan proceeds and before the $70 million going out the door. The balance sheet is still strong, but the trajectory has turned — this is the first quarter in two years where net cash is not the bull case

Japan, and the two-week leash

The second commercial pillar launched on October 14, and Meeker did not hedge: “We have every expectation that Japan will become our second-largest market.” — David Meeker, CEO · 2026-11-03 The setup is unusually good for a first-year rare disease launch — 350 priority hospitals identified, 300 already engaged, over 1,000 potentially eligible patients found, 50-plus employees, national reimbursement at $2,200 per vial (60% of U.S. WAC, set for ten years), and a Japan Endocrine Society guideline plus a joint society statement on appropriate use landing in September and October. But Yann Mazabraud was refreshingly blunt about the structural brake: first-year prescriptions are limited to a two-week supply, forcing patients back to hospital every fortnight until the restriction lifts in November 2027. That is a deliberately deferred revenue curve, and management is asking investors to underwrite years two and three rather than quarters one and two. Given the stock's drawdown, the market is doing the opposite.

Prader-Willi: the endpoint that quietly changed

This is the most underappreciated line in the call. In November 2025, Meeker told investors the opposite of what he said this week: “our primary endpoint here is BMI percent change... We wouldn't pursue a hyperphagia label only.” — David Meeker, Chief Executive Officer · 2025-11-04 In February 2026 he repeated it: “our goal remains the same. We'd be looking to clear 5% on the BMI change.” — David Meeker, Chief Executive Officer (CEO) · 2026-02-26 Now the PWS registrational study is a six-month design with HQ-CT — the hyperphagia questionnaire — as the primary endpoint, with BMI change collected but relegated to label-supporting detail. Meeker's justification is candidly regulatory rather than biological: “when Soleno, now Neurocrine, when their drug, VYKAT, was approved by the FDA, as is often the case with first approvals, they set a bit of a precedent and a template for others to follow.” — David Meeker, CEO · 2026-11-03 A six-month hunger trial beats a twelve-month BMI trial to the FDA by half a year, and payers — in his framing — follow labels rather than endpoints. That is smart drug development and it is also a de-risking of the pipeline's largest optionality, because BMI at twelve months was always the harder read in a disease with this much behavioral noise. It deserves more discussion than the eight minutes it got.

The bottom line

Rhythm is a company that spent five calls telling analysts the launch would be steady — “Is there any sign of an early launch bolus?” — Philip Nadeau, Analyst · 2026-08-04 was the recurring question, and "no bolus" was the recurring answer — and then delivered 29% sequential growth anyway. It is now spending real money to own its own economics, opening a second major market, and quietly swapping the endpoint that defines its biggest pipeline asset. The enterprise value says investors want proof on duration; the operating numbers say duration is exactly what is being bought. R&D is running at roughly 60% of revenue, but the royalty buy-down converts a variable cost into a fixed one, so every incremental HO dollar now drops through faster